Responses
Clinical/translational cancer immunotherapy
Original research
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
Compose a Response to This Article
Other responses
No responses have been published for this article.